Skip to main content
. 2004 Aug 5;63(12):1664–1669. doi: 10.1136/ard.2003.012450

Figure 3.

Figure 3

 Percentage of patients presenting peripheral arthritis (A) or active enthesitis (B) at baseline and during the treatment (45 days, 3, 6, 12, 18 months) with infliximab or various other drugs (azathioprine, mesalazine, steroids, metronidazole, antibiotics). *The data reported at 12 months are relative to patients (10/21) who prolonged the treatment with infliximab for up to 12 months; no controls are available for this group.